Tonix Pharmaceuticals (NASDAQ:TNXP) Earns Outperform Rating from Noble Financial

Tonix Pharmaceuticals (NASDAQ:TNXP)‘s stock had its “outperform” rating reaffirmed by research analysts at Noble Financial in a research note issued to investors on Thursday,Benzinga reports. They currently have a $70.00 price target on the stock. Noble Financial’s price target suggests a potential upside of 203.95% from the company’s previous close.

Separately, StockNews.com started coverage on shares of Tonix Pharmaceuticals in a research note on Monday, February 10th. They issued a “sell” rating on the stock.

Tonix Pharmaceuticals Trading Up 26.6 %

NASDAQ:TNXP opened at $23.03 on Thursday. The company’s 50-day simple moving average is $18.44 and its 200 day simple moving average is $19.74. The firm has a market capitalization of $43.04 million, a P/E ratio of 0.00 and a beta of 2.23. Tonix Pharmaceuticals has a one year low of $6.76 and a one year high of $1,146.01. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.33 and a quick ratio of 2.81.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its earnings results on Tuesday, March 18th. The company reported ($9.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($6.23) by ($3.54). The firm had revenue of $2.58 million during the quarter, compared to the consensus estimate of $3.20 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. As a group, analysts forecast that Tonix Pharmaceuticals will post -1762.5 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC increased its holdings in Tonix Pharmaceuticals by 1,600.1% during the fourth quarter. Geode Capital Management LLC now owns 1,971,894 shares of the company’s stock valued at $650,000 after buying an additional 1,855,907 shares during the last quarter. Jane Street Group LLC increased its holdings in Tonix Pharmaceuticals by 5,932.3% during the fourth quarter. Jane Street Group LLC now owns 1,662,682 shares of the company’s stock valued at $548,000 after buying an additional 1,635,119 shares during the last quarter. Point72 Asset Management L.P. purchased a new stake in Tonix Pharmaceuticals during the fourth quarter valued at approximately $526,000. Northern Trust Corp purchased a new stake in Tonix Pharmaceuticals during the fourth quarter valued at approximately $162,000. Finally, PFG Investments LLC purchased a new stake in Tonix Pharmaceuticals during the fourth quarter valued at approximately $72,000. Institutional investors own 82.26% of the company’s stock.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.